<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Zacks Small Cap Research Press Releases </title><link>https://scr.zacks.com/</link><description>generated by Q4</description><category /><lastBuildDate>Sat, 21 Nov 2026 14:35:37 -0500</lastBuildDate><copyright>Copyright Q4 Inc. All rights reserved.</copyright><item><title>HIT: Looking to 2027 to Leverage 2026 Growth Initiatives; Recent Measures Aim to Maximize Operational Efficiency, Support Growth</title><guid>91c8743c-2c62-475d-a0d6-8085f1ad0f98</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=24b66996-a41f-4d55-90ca-17a197076cc2"&gt;M. Marin&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: HIT&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11202026_HIT_Marin.pdf"&gt;READ THE FULL HIT RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;strong&gt;Looking to 2027 to leverage ‘26 growth initiatives, recent measures aim to optimize new product deployments, maximize operational efficiency &amp; support growth&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Health in Tech (NASDAQ: HIT), an AI-enabled InsurTech platform, reported 3Q26 results last week. With an eye to 2027 as a year of leveraging the many growth initiatives made over the last several quarters, HIT has implemented recent measures aimed at optimizing deployments of new products and solutions and maximizing operational efficiency. Among these, last month HIT appointed a new Chief Executive Officer, Sanjay Shrestha, as the company looks to build on the infrastructure it has established to support growth. He previously served as a director on and strategic advisor to HIT's board, which along with his earlier professional experience, HIT expects will enhance its operational success going forward. HIT Founder Tim Johnson has transitioned to Executive Chairman.&lt;/p&gt;

&lt;p&gt;The company has also named a new Independent Director, Chair of the Compensation Committee, and appointed a new board director who has significant Wall Street research and capital markets experience. We believe the board changes are aimed at balancing capital needs with goals of minimizing dilution, among other factors. To the extent that HIT potentially can better align insider interests more closely with those of shareholders, we would view that positively.&lt;/p&gt;

&lt;p&gt;As indicated previously, HIT has laid the groundwork for growth going forward, including introducing new enhancements such as large-employer underwriting and a 3-year rate hold for large employers, among others. As HIT adds new features, combining AI-driven automation and underwriting support with human quality control, and as revenue is anticipated to grow, the company expects to further increase its operating leverage. Into 2027, management indicated that its priorities include scaling HitRix, advancing HITChain, expanding distribution and evaluating strategic growth opportunities including potential complementary M&amp;A to help re-accelerate growth. In terms of expanding distribution, HIT announced that a national third-party administrator (TPA) serving more than 650 employers and covering more than 100k employees is now live on the company's eDIYBS platform.&lt;/p&gt;

&lt;p style="text-align: center;"&gt;&lt;a href="https://filecache.investorroom.com/mr5irasia_hit/244/Health_In_Tech_Q3_2026_Quarterly_Presentation.pdf"&gt;&lt;img src="//s27.q4cdn.com/906368049/files/pictures/2026/11202026_HIT_1.png" style="width: 750px;" /&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;3Q26 results were mixed, we believe, regarding the benefits of the many growth measures launched in 2026. For example, revenue was $6.6 million, compared to $8.5 million in 3Q25, but pipeline revenue was $156.4 million as of October 30, 2026, up from $66.3 million as of July 31, 2026. Pipeline revenue represents policies that are in quoting or binding status. Currently, the company’s rule of thumb implies an expected conversion rate of 3% to 7% of pipeline revenue will be realized as revenue, which would equate to about $4.7 million to $10.9 million. Among the many goals the new CEO has is the goal to boost that conversion rate substantially.&lt;/p&gt;

&lt;p&gt;The company attributed the substantial increase of its sales pipeline to the full completion of onboarding new carriers, entering into the peak sales season ahead of December and January policies effective dates and expanding its distribution network, which grew by roughly 15.9% year-over-year.&lt;/p&gt;

&lt;p&gt;The year-over-year 3Q26 revenue decline primarily reflects timing of onboarding new carriers, which shifted effective start dates of some policies forward. In 2Q26, HIT onboarded a new carrier partner and the effective dates of several policies shifted forward. When the company sells a policy, it does not recognize 100% of the revenue upfront, but ratably on a monthly basis over the 12- to 36-month life of the policy. The company believes the carrier transition is substantially completed at this point.&lt;/p&gt;

&lt;p&gt;Going forward, HIT is focused on accelerating policy onboarding, improving conversion rates, and translating its existing pipeline into 2027 revenue growth. In addition to improving its execution and operating performance and scaling existing business, the new CEO will also lead activities around identifying and evaluating potential strategic acquisitions and partnerships, among other prospective opportunities.&lt;/p&gt;

&lt;p style="text-align: center;"&gt;&lt;a href="https://filecache.investorroom.com/mr5irasia_hit/244/Health_In_Tech_Q3_2026_Quarterly_Presentation.pdf"&gt;&lt;img src="//s27.q4cdn.com/906368049/files/pictures/2026/11202026_HIT_2.png" style="width: 750px;" /&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt; to receive our articles and reports emailed directly to you. Please visit our &lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt; for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/HIT-Looking-to-2027-to-Leverage-2026-Growth-Initiatives-Recent-Measures-Aim-to-Maximize-Operational-Efficiency-Support-Growth-article/default.aspx</link><pubDate>Fri, 20 Nov 2026 15:02:00 -0500</pubDate></item><item><title>RERE: Deftly Navigating A Challenging Smartphone Market. Outlook Remains Bright For A True Small-Cap Value in 2027.</title><guid>6e9980b8-6822-4b78-9af8-e58bf2ab2c45</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=62bee72e-c05c-4e91-af47-a8878d9b2726"&gt;Brian Lantier, CFA&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NYSE: RERE&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11202026_RERE_Lantier.pdf"&gt;READ THE FULL RERE RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;ATRenew (NYSE: RERE) reported strong third-quarter results on November 19, with revenue growth above previously issued guidance and reported sales roughly in line with our model at RMB 6.45 billion (versus our forecast of RMB 6.4 billion). The market for new consumer electronics continues to be pressured by rising memory costs, which have increased prices across all categories, including new and refurbished merchandise. The company is also navigating its first Apple iPhone launch cycle with staggered releases (the more expensive Pro models launching in 2026, while base models will not launch until 2027), which may change the business's normal seasonality.&lt;/p&gt;

&lt;p&gt;The company's balance sheet remains remarkably strong, with close to RMB 1.5 billion ($220 million) in cash and short-term investments as of 9/30/26, representing about 25% of the company's total assets. Inventory levels have risen, but we believe this is largely due to higher price points for many products acquired amid rising memory costs. As long as customers are willing to absorb higher prices for consumer electronics and smartphones, and inventory turnover remains brisk, we are not concerned about rising inventory levels.&lt;/p&gt;

&lt;p&gt;While management did not provide guidance for fiscal 2027, the company's guidance for the fourth quarter of RMB 7.78 billion to RMB 7.88 billion was about 10% above our previous estimate. Early reports indicate that consumer demand for the iPhone Pro, Pro Max, and Folding Duo has been strong in China despite their higher price points. We think that this strength in Apple products, despite Apple not yet having released a base model, is driving much of ATRenew's confidence in Q4 results. We are electing to be a little more conservative with our model right now. We will wait to see additional shopping reports from the 11/11 and 12/12 shopping holidays before adjusting our revenue forecast (now at RMB 7.65 billion) higher.&lt;/p&gt;

&lt;p&gt;The third quarter results confirm our thesis that ATRenew can thrive even in a challenging market for consumers and consumer electronics. The company has not provided 2027 guidance at this point; we are currently forecasting 17% topline growth in 2027, but the quarterly breakdown may depend upon smartphone release timelines next year.&lt;/p&gt;

&lt;p&gt;Shifts in the consumer electronics market in 2026 have created challenges and opportunities for ATRenew. Higher memory costs and lower unit shipments of new devices have increased the industry’s focus on recycling efforts and strengthened ATRenew’s position in the market and the industry. The power of the company’s brand has enabled it to expand its multiline store offerings, and the benefits of additional product line diversification have yet to be fully appreciated by investors. International expansion continues at a measured pace, providing meaningful growth opportunities over the next 5 years. We would encourage investors to read our full updated report on one of the most compelling values in our coverage universe.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt;&amp;nbsp;to&amp;nbsp;receive our articles and reports emailed directly to you. Please visit our&amp;nbsp;&lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt;&amp;nbsp;for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/RERE-Deftly-Navigating-A-Challenging-Smartphone-Market--Outlook-Remains-Bright-For-A-True-Small-Cap-Value-in-2027-article/default.aspx</link><pubDate>Fri, 20 Nov 2026 12:16:00 -0500</pubDate></item><item><title>AEON: Third Quarter Results</title><guid>f2530a27-6694-418b-bbaf-13d17a55b88b</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=dd01b998-53e1-4448-9b1a-8fe0a6a3c606"&gt;John Vandermosten, CFA&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NYSE: AEON&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11202026_AEON_Vandermosten.pdf"&gt;READ THE FULL AEON RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;AEON Biopharma, Inc. (NYSE: AEON) reported third quarter 2026 financial results in a November 16&lt;sup&gt;th&lt;/sup&gt; &lt;a href="https://investors.aeonbiopharma.com/news-releases/news-release-details/aeon-biopharma-reports-third-quarter-2026-financial-results-and"&gt;press release&lt;/a&gt;. During the second half of 2026, the company has raised funds from a public offering and warrant exercise, added an acting Chief Regulatory Officer, compared ABP-450 to Botox with respect to molecular similarity and forced degradation results and received feedback from the FDA Type 2b meeting. Just prior to the third quarter report, AEON announced that it had submitted the investigational new drug (IND) application to run the compound muscle action potential (CMAP) pharmacodynamic (PD) study. It is preparing to launch the PD study along with bridging studies to follow the guidance provided by the FDA in its most recent meeting.&lt;/p&gt;

&lt;p&gt;During the third quarter, AEON reported an operating loss of $4.5 million and no revenues. Cash burn in the quarter was $5.7 million offset by $13.7 million of cash from financing. Cash and equivalents stand at $11.4 million with a post quarter end cash infusion of $6.2 million from warrant exercise.&lt;/p&gt;

&lt;p&gt;AEON has made steady progress advancing ABP-450 along the path towards FDA approval of biosimilarity. In parallel, the FDA has indicated its willingness to shift its emphasis towards reliance on analytical evidence and less routine, duplicative clinical testing. The most impactful differences address comparative efficacy trials, foreign comparator/pharmacokinetic (PK) bridging studies and the evidence needed for interchangeability. FDA has also updated analytical-quality and post-approval manufacturing guidance. While the headline changes remain draft recommendations, we anticipate that these changes will streamline the path forward for AEON to advance ABP-450 towards a Biologics License Application (BLA).&lt;/p&gt;

&lt;p&gt;With partner Daewoong already manufacturing ABP-450 for Evolus’ FDA-approved Jeuveau, we see a competitive advantage from having a partner who is already producing the product and one that has already received FDA approval for an aesthetic indication. Below we summarize the key reasons to own AEON shares:&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;2026 Year-to-Date Review&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;2026 &lt;a href="https://investors.aeonbiopharma.com/news-releases/news-release-details/aeon-biopharma-reports-bpd-type-2a-meeting-fda-and-shareholder"&gt;began&lt;/a&gt; with AEON holding its Biological Product Development (BPD) Type 2a meeting with the FDA. The gathering &lt;a href="https://investors.aeonbiopharma.com/news-releases/news-release-details/aeon-biopharma-announces-fda-feedback-following-bpd-type-2a"&gt;later&lt;/a&gt; provided AEON with official meeting minutes regarding the company’s analytical similarity strategy. The agency noted that the analytical methodologies appeared reasonable and supported advancement of the program toward the compilation of a comprehensive analytical similarity package. AEON received the minutes from the BPD Type 2b meeting in September, which generated targeted advice on biosimilar development including study design and the next phase of development.&lt;/p&gt;

&lt;p&gt;Feedback from the Fall 2026 Type 2b meeting fired the starting gun for the filing of an IND, which was announced as complete in early November. We expect to see the subsequent start of a PD study in the first quarter of 2027. Along with the PD study, AEON plans bridging studies for several ABP-450/Botox head-to-head trials conducted by Daewoong. The minutes identify a clear plan to support a 351(k) biosimilars submission. A comparative efficacy study was not recommended at this time but this requirement could change depending on the next tranche of data. The agency has been emphasizing analytical work and only requiring further evidence of similarity when there are unanswered questions.&lt;/p&gt;

&lt;p&gt;The FDA agreed in principle with AEON’s proposed two-stage design for a comparative pharmacodynamic study using CMAP measurement in the extensor digitorum brevis muscle, consisting of an initial dose-finding stage followed by a comparative pharmacodynamic evaluation and provided recommendations intended to strengthen the study’s ability to demonstrate assay sensitivity.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Operating and Financial Results&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;On November 16&lt;sup&gt;th&lt;/sup&gt;, 2026, AEON &lt;a href="https://investors.aeonbiopharma.com/news-releases/news-release-details/aeon-biopharma-reports-third-quarter-2026-financial-results-and"&gt;reported&lt;/a&gt; 3Q:26 financial and operating results and filed its &lt;a href="https://investors.aeonbiopharma.com/static-files/e13034a1-3431-458c-8b84-350af1fdec3c"&gt;Form 10-Q&lt;/a&gt; with the SEC. AEON generated no revenues in 3Q:26 and posted an operating loss of $4.5 million, with expenses rising by 80% largely due to higher compensation expenses. Net income was positive and approximately $2.5 million; however, it was impacted by a non-cash $7.0 million increase in fair value of warrants. For the quarter ending September 30&lt;sup&gt;th&lt;/sup&gt;, 2026 and versus the corresponding prior year quarter:&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;Selling, general &amp; administrative expenses totaled $3.0 million, increasing 55% from $1.9 million. The increase was primarily attributable to higher payroll-related expenses, including stock-based compensation and increased headcount, expenses related to the relocation of AEON’s corporate office, including $0.3 million related to the impairment of the right-of-use asset for the former office lease and the loss on disposal of fixed assets. These increases were partially offset by lower professional fees, related to the Odeon settlement in the prior year period;&lt;/li&gt;
&lt;li&gt;Research &amp; development expense totaled $1.5 million, up 154% from $0.6 million. The prior year amount was impacted by a $0.6 million gain on the settlement of liabilities from AEON’s clinical research organization that offset R&amp;D expenses. Other factors driving the increase include greater payroll-related expenses related to increased headcount partially offset by lower accrued bonus expense;&lt;/li&gt;
&lt;li&gt;Other income of $6.9 million compared to a $2.0 million loss with the difference attributable to a favorable change in fair value of warrants in contrast to a detrimental change in fair value of convertible notes in the prior year period;&lt;/li&gt;
&lt;li&gt;No provision for income taxes was made in either period;&lt;/li&gt;
&lt;li&gt;Net income was $2.5 million or $0.01 per share&lt;a href="#_ftn1" name="_ftnref1"&gt;&lt;sup&gt;[1]&lt;/sup&gt;&lt;/a&gt; vs a $4.5 million loss or $0.39 per share.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;As of September 30&lt;sup&gt;th&lt;/sup&gt;, 2026, AEON held $11.4 million in cash on its balance sheet and $2.0 million of convertible notes. Cash burn for the first nine months of 2026 was $12.1 million while cash flows from financing were $20.5 million. Financing transactions from a public offering, PIPE financing and an ATM facility contributed to the company’s coffers. Following the end of the quarter, AEON received proceeds of approximately $6.2 million from the exercise of milestone warrants. AEON notes in its 3Q:26 10-Q filing that it has sufficient cash to support operations into the second quarter of 2027. The launch of additional studies, preparation for future FDA meetings and any further development of ABP-450 will require additional funding in the form of equity financings or debt.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt;&amp;nbsp;to&amp;nbsp;receive our articles and reports emailed directly to you. Please visit our&amp;nbsp;&lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt;&amp;nbsp;for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;________________________ &lt;/p&gt;

&lt;p&gt;&lt;sup&gt;&lt;a href="#_ftnref1" name="_ftn1"&gt;[1]&lt;/a&gt; We note that AEON uses a higher share count to calculate average basic shares outstanding that includes the impact of warrants, common stock options, restricted stock units and assumed converted convertible notes to generate its $0.01 share result.&lt;/sup&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/AEON-Third-Quarter-Results-article/default.aspx</link><pubDate>Fri, 20 Nov 2026 11:58:00 -0500</pubDate></item><item><title>AMS: Direct Patient Services Revenue up 14% Y/Y in 3Q26 &amp; 27% in 1st 9 Months ’26</title><guid>4cc245ba-29c0-4ef3-9722-00afb8dbd61c</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=24b66996-a41f-4d55-90ca-17a197076cc2"&gt;M. Marin&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NYSE: AMS&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11192026_AMS_Marin.pdf"&gt;READ THE FULL AMS RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;strong&gt;Expanded O&amp;O footprint contributes to strong revenue growth…&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;American Shared Hospital Services (NYSE: AMS), which provides and operates advanced radiation therapy treatment systems to treat cancer patients, reported 3Q26 results last week that we believe underscore the benefits of its ongoing transition to a company that both leases costly cancer treatment medical equipment and also owns and operates (O&amp;O) the equipment itself in many select markets, as the company continues to expand its Direct Patient Services operations. Direct Patient Services revenue increased 14% year-over-year in 3Q26 and 27.0% year-over-year in the first nine months of 2026.&lt;/p&gt;

&lt;p&gt;The company attributed the growth largely to continued growth in its Rhode Island radiation therapy operations and higher procedure volumes at its international Gamma Knife facilities. Radiation therapy procedures at the Direct Patient Services segment facilities totaled 7,143, compared with 7,355 in 3Q25. International Gamma Knife procedures in Peru and Ecuador increased 8.9% year-over-year. The company benefited from the upgrade of its Peru facility to a Gamma Knife Esprit system in June 2025. The upgraded system provides shorter treatment times, supporting increased procedure volume. The upgrade to an Esprit system in Lima, Peru during 2025 brings newer generation technology to the center and is expected to expand the company’s treatment capabilities there to support future growth. As noted, it has reduced treatment times and improved patient throughput, which in turn contributes to stronger operating performance at the Peru O&amp;O location. The company remains focused on increasing utilization across its O&amp;O network and improving operational performance, while strengthening its financial position. Revenue and the financial performance of the Direct Patient Services segment can also be impacted by reimbursement levels, market conditions and operating costs.&lt;/p&gt;

&lt;p&gt;Direct Patient Services segment growth contributed to 3Q26 total revenue growth of 6.3% to $7.6 million, with the Direct Patient Services segment growth partially offset by a slight decline in revenue of the Medical Equipment Leasing segment to $3.0 million, compared with $3.1 million in 3Q25. With the strong foundation for growth in the Direct Patient Services segment, the company’s goal is to optimize its cost structure further and improve operating performance while concurrently strengthening its balance sheet and financial position.&lt;/p&gt;

&lt;p&gt;In terms of its balance sheet, AMS generated $5.8 million in cash flow year-to-date through 3Q26, contributing to a cash, cash equivalents and restricted cash balance of roughly $9.5 million at September 30, 2026, compared with $3.7 million at December 31, 2025.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;strong&gt;San Javier Joint Venture (JV)&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;The company is pursuing additional opportunities to expand its reach and capabilities, building on its established presence in radiation oncology and leverage its capabilities and relationships with leading healthcare institutions. For example, its joint venture with Hospital San Javier in Guadalajara, Mexico, represents another opportunity to extend its Gamma Knife presence into a new market.&lt;/p&gt;

&lt;p&gt;AMS expects to upgrade the hospital's existing Gamma Knife Perfexion system to a Gamma Knife Esprit system and expects patient treatments at the facility to begin in mid-2027. This would extend the Direct Patient Services segment Gamma Knife reach into another market, as noted, and the segment’s international platform. The company believes its portfolio of oncology treatment centers positions AMS to participate across multiple areas of cancer treatment.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;strong&gt;Plus additional O&amp;O expansion projects in RI&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Additional O&amp;O expansion projects and potential catalysts for long-term growth include the planned construction of two new centers in RI. AMS believes its facilities operate in underserved areas of Rhode Island. Moreover, with only two PBRT systems currently in operation in the northeast, according to AMS, the company also believes the location of the planned facility enables access to this treatment and will enable many Rhode Island cancer patients to avoid the need to travel to Boston or New York for critical care.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt;&amp;nbsp;to&amp;nbsp;receive our articles and reports emailed directly to you. Please visit our&amp;nbsp;&lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt;&amp;nbsp;for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/AMS-Direct-Patient-Services-Revenue-up-14-Y-Y-in-3Q26--27-in-1st-9-Months-26/default.aspx</link><pubDate>Thu, 19 Nov 2026 17:02:00 -0500</pubDate></item><item><title>APVO: RAINIER Phase 1b Dose Optimization Study Completion by Year-End 2026</title><guid>93018a50-2c3b-4c85-a832-99a47c254287</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=e38a3af7-5620-44ff-b299-706e26bed702"&gt;David Bautz, PhD&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: APVO&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11192026_APVO_Bautz.pdf"&gt;READ THE FULL APVO RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Business Update&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Mipletamig Continues to Generate Encouraging Clinical Evidence in Frontline AML&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Aptevo Therapeutics, Inc. (NASDAQ: APVO) has provided a number of important recent clinical updates that show the potential for mipletamig as a differentiated treatment option for patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive induction chemotherapy. The most compelling developments remain the accumulating clinical activity observed in combination with venetoclax and azacitidine, including encouraging results in patients with TP53-mutated AML and the increasing number of patients proceeding to allogenic stem cell transplantation following treatment. Importantly, Aptevo has also addressed a meaningful clinical development objective by substantially reducing infusion-related reactions (IRRs) through refinements to mipletamig’s priming-dose regimen. Together, these advancements strengthen the clinical rationale for advancing mipletamig into Phase 2 development as the company moves toward the end of the RAINIER Phase 1b dose optimization study by the end of 2026.&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;In September 2026, Aptevo reported particularly encouraging results in patients with TP53-mutated AML, a population associated with poor outcomes and limited treatment options. Among 14 evaluable patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose-expansion study, 13 (93%) experienced clinical benefit, defined as complete response (CR), complete response with incomplete hematologic recovery (CRi), partial response (PR), and morphologic leukemia-free state (MLFS). Eleven patients (79%) achieved CR/CRi, including nine CRs. The 79% CR/CRi rate compares favorably with the approximately 41% CR/CRi rate reported in the published study of treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML receiving venetoclax and azacitidine alone.&lt;/li&gt;

&lt;li&gt;In October 2026, Aptevo reported that 10 of 47 evaluable frontline patients treated with mipletamig plus venetoclax and azacitidine had proceeded to transplantation, including nine patients from the ongoing RAINIER trial and one from the completed dose-expansion study. This represents approximately 21% of the reported patient population. The finding is noteworthy because these patients were initially considered unsuitable for intensive induction chemotherapy, a population in which age, comorbidities, and disease characteristics can limit access to transplantation.&lt;/li&gt;

&lt;li&gt;On November 5, 2026, Aptevo announced that the successive refinements to mipletamig’s priming-dose regimen had substantially reduced the frequency and severity of infusion-related reactions. The development addresses an important treatment-tolerability objective identified through the company’s discussions with the FDA and represents a meaningful step in optimizing the mipletamig dosing regimen ahead of Phase 2 development.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mipletamig has previously demonstrated an encouraging safety profile, including favorable findings related to cytokine release syndrome (CRS). However, infusion-related reactions remain a practical consideration for antibody-based therapies, particularly in frontline AML patients who are often older and may have additional health conditions. IRRs can require additional medical intervention, interrupt treatment, or contribute to treatment discontinuation. Thus, reducing their frequency and severity could improve the overall treatment experience and potentially make mipletamig easier to administer alongside venetoclax and azacitidine.&lt;/p&gt;

&lt;p&gt;The company also indicated that the refined priming-dose approach substantially reduced IRRs without compromising the planned therapeutic dosing. This achievement is important because it addresses a specific development hurdle and improves mipletamig’s overall development profile, particularly as the company prepares to select an optimized dose for Phase 2 evaluation.&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;We anticipate the completion of the ongoing Phase 1b RAINIER dose-optimization study by year-end 2026, followed by regulatory interactions during the first half of 2027 and initiation of the Phase 2 development in 2027.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;em&gt;Update on Multispecific Pipeline&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Beyond mipletamig, Aptevo continues to advance its next-generation multispecific immunotherapy platform. At the November 7 Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, Aptevo presented new preclinical findings involving APVO451, APVO452, and APVO711. The studies focused on overcoming immunosuppressive mechanisms within the tumor microenvironment, an important obstacle to the effectiveness of many existing cancer immunotherapies. A copy of the poster can be found &lt;a href="https://aptevotherapeutics.gcs-web.com/static-files/b57176f2-50c1-451a-ab63-6ed7025c9496"&gt;here&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;APVO451 and APVO452 combine CD40 activation with T cell engagement, bringing together mechanisms intended to stimulate an anti-tumor response and direct T cells toward cancer cells. In preclinical studies, both candidates demonstrated T cell activation and tumor cell killing under immunosuppressive conditions. APVO711 takes a different approach by combining CD40 activation and PD-L1 checkpoint blockade, targeting two separate mechanisms involved in suppressing anti-tumor immunity. The results provide preliminary validation of Aptevo’s ability to engineer multispecific molecules that engage complementary immune pathways within the tumor microenvironment.&lt;/p&gt;

&lt;p&gt;An additional recent milestone for the company’s multispecific platform is the progress in optimizing manufacturing processes for its next-generation trispecific molecules. Aptevo indicated that the improvements are helping address the technical challenges associated with producing complex multispecific therapeutics reliably and at the scale required for further development. This is an important consideration for the platform, as manufacturing complexity can become a significant obstacle when moving engineered antibody-like molecules from laboratory research into clinical development.&lt;/p&gt;

&lt;p&gt;The company also disclosed a new patent application covering Nectin-4 x PD-L1 dual-targeting technology. This approach could support both immune-based therapies and radiopharmaceutical applications, potentially extending the utility of Aptevo’s technology beyond conventional multispecific immunotherapy. The development is particularly relevant to the company’s collaboration with Niowave, which is focused on developing up to three radiopharmaceutical oncology programs, with the first expected to target Nectin-4. Aptevo continues to anticipate that the first radiopharmaceutical candidate and its internally developed solid tumor program will advance into IND-enabling studies during 2027.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Financial Update&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;On November 16, 2026, Aptevo announced financial results for the third quarter of 2026. As expected, the company did not report any revenue in the third quarter of 2026. R&amp;D expenses in the third quarter of 2026 were $3.7 million compared to $4.0 million for the third quarter of 2025. The decrease was primarily due to lower supply, lab, and consulting costs partially offset by higher clinical and employee costs. G&amp;A expenses in the third quarter of 2026 were $2.9 million compared to $3.6 million in the third quarter of 2025. The decrease was primarily due to lower employee costs.&lt;/p&gt;

&lt;p&gt;Aptevo exited the third quarter of 2026 with approximately $8.3 million in cash and cash equivalents. In August 2026, the company entered into warrant inducement letter agreements with certain holders of existing warrants, in which those holders agreed to exercise in full for cash their existing warrants to purchase up to an aggregate 254,922 shares of common stock for $4.03 per share. Concurrently, Aptevo entered into a private placement with certain purchasers for the sale of up to 861,708 unregistered shares of common stock at a price of $4.03. The aggregate net proceeds from the transactions were approximately $4.1 million. As of November 14, 2026, Aptevo had approximately 3.5 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 9.6 million.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Conclusion&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Aptevo continues to make steady progress in the development of mipletamig in frontline AML along with the multispecific platform. The next several months should be important for the company, with the completion of the RAINIER dose optimization study targeted for year-end 2026, presentation of additional data at ASH in December 2026, and planned regulatory interactions during the first half of 2027. These developments should provide greater clarity regarding the optimal mipletamig regimen and the design of the next-stage clinical program. The company’s progress in advancing the multispecific candidates also provides additional long-term pipeline optionality. Unfortunately, the stock has continued to face considerable pressure in the past few months, which has resulted in an increase in the number of future shares we estimate will need to be issued to finance operations. Our valuation now stands at $20 per share.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt;&amp;nbsp;to&amp;nbsp;receive our articles and reports emailed directly to you. Please visit our&amp;nbsp;&lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt;&amp;nbsp;for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/APVO-RAINIER-Phase-1b-Dose-Optimization-Study-Completion-by-Year-End-2026-article/default.aspx</link><pubDate>Thu, 19 Nov 2026 14:02:00 -0500</pubDate></item><item><title>SEV: Delivers Its First Vehicle. Will 2027 Finally Be Aptera’s Year?</title><guid>7701cff2-1ad6-47b4-a25a-3ddda2b5736b</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=62bee72e-c05c-4e91-af47-a8878d9b2726"&gt;Brian Lantier, CFA&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: SEV&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11192026_SEV_Lantier.pdf"&gt;READ THE FULL SEV RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;On the morning of November 19th, Aptera Motors (NASDAQ: SEV) revealed that it has completed its first vehicle for sale to a customer, marking a major milestone in the company’s history and meeting its stated goal of “customer deliveries in 2026”.&lt;/p&gt;

&lt;p&gt;Earlier in the week, the company began teasing that it would have a major announcement after its earnings release with a countdown timer on its website, a tactic that the company seems to have borrowed from Tesla’s Cybertruck and Roadster launches.&lt;/p&gt;

&lt;p&gt;After 20 years of developing the solar electric vehicle concept and more than seven years since the company was relaunched in 2019, Aptera has finally announced that it has completed delivery to the customer holding the Accelerator #1 position on its reservation list. The company did not reveal any information about the pricing of the first vehicle, but we expect to hear more about pricing as future deliveries are confirmed.&lt;/p&gt;

&lt;p&gt;As we noted in our most recent update, the company has been hyper-focused on meeting its goal of “delivering customer vehicles in 2026,” and we speculated at the time that it might announce a handful of customer deliveries to meet that goal.&lt;/p&gt;

&lt;p&gt;The company’s next focus will likely shift to delivering the first batch of 40 vehicles. We anticipate that the bulk of these deliveries will take place in early 2027, but there remains some uncertainty about their timing.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Q3 Earnings&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;On November 12, Aptera reported the results for the company's third quarter of 2026, ended September 30. The company was still testing its validation vehicles in the third quarter and thus did not recognize any revenue from vehicle sales. The company's expenses increased meaningfully, driven by higher R&amp;D expenditures, as management focused on vehicle validation.&lt;/p&gt;

&lt;p&gt;The company's total net loss increased to almost $14 million for the quarter (up roughly 28% sequentially from Q2) primarily due to higher R&amp;D expenditures. Operating cash used in the quarter remained above $7 million, and we believe the burn rate will likely remain in the $2-$3 million per month range until production begins to accelerate.&lt;/p&gt;

&lt;p&gt;As we noted in our Q3 earnings preview, the company announced on November 10 that it had secured an agreement with institutional investors to raise $6 million through a registered direct offering. The primary terms of the offering were the issuance of 3.43 million Class B shares at $1.75 per share and 3.43 million warrants granted to the investors in the private placement, with an exercise price of $2.05 per share. The total gross proceeds are anticipated to be $6 million, and we assume that the company will net about $5.6 million. The company also indicated that, subsequent to the quarter-end, it had raised an additional roughly $600k in net proceeds under its equity line of credit and at-the-market facility.&lt;/p&gt;

&lt;p&gt;At the end of September, Aptera had $9.1 million of cash on its balance sheet and has been burning roughly $2.5 million per month in 2026. Using that burn rate as an estimate and adding the proceeds from the private placement, equity line, and at-the-market facility accessed since the end of the quarter (total net proceeds of roughly $6.2 million), we believe that it is likely Aptera will end the month of November with around $10 - $10.5 million in cash on the balance sheet.&lt;/p&gt;

&lt;p&gt;Despite achieving a major milestone and delivering its first vehicle to a customer, Aptera's shares remain under meaningful pressure and have revisited the lows hit after the latest round of financing was announced. We remain concerned that, with the shares trading just above their all-time low heading into the last month of the year, tax-loss selling could accelerate just as the company seeks a meaningful round of financing.&lt;/p&gt;

&lt;p&gt;Our model will likely need continuous adjustments over the next 12 months as we attempt to model the timing of low-volume production with several factors such as component costs, the vehicle's final price, and initial customer demand largely unknown. We also assume that the company will be able to successfully access capital to fund operations through the second half of 2028, when we expect it could turn cash flow positive. We currently anticipate that the company will issue up to an additional 20 million shares at prices between $2.00 and $5.00 to fund its shift to low-volume production, but if the capital is raised at prices closer to the current price, we may have to adjust our assumptions for total share count and our ultimate price target.&lt;/p&gt;

&lt;p&gt;We encourage investors to review our full updated research report for additional information.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt; to receive our articles and reports emailed directly to you. Please visit our &lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt; for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/SEV-Delivers-Its-First-Vehicle--Will-2027-Finally-Be-Apteras-Year-article/default.aspx</link><pubDate>Thu, 19 Nov 2026 13:02:00 -0500</pubDate></item><item><title>DFNS: AI Data Center Comes Online to Power T3 Defense's Subsidiaries</title><guid>5f8e5680-f133-423b-a647-a23fc5af053e</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=7ce34d3d-cd10-4880-9ebc-b4e88e6e7037"&gt;Tom Kerr, CFA&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: DFNS&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;T3 Defense (NASDAQ: DFNS) switched on its new T3 AI Data Center on November 15, 2026. It’s a shared computing hub for engineering, AI development and production management across the company’s defense subsidiaries. The facility sits inside Bezeq International’s site in Rosh HaAyin, Israel, so each subsidiary gets dedicated computing power without having to build and run its own setup. Rimon Agencies, the engineering and systems integration arm, is the first one on board. It’s using the platform for production-floor operations and engineering project management.&lt;/p&gt;

&lt;p&gt;The data center is run by seven Dell PowerEdge R760 servers, 14 NVIDIA professional GPUs, 672GB of total GPU memory and 20TB of storage. That’s enough muscle for engineering simulations, AI development and digital production management. The site is Tier III and ISO-certified, with physical and cyber protections, redundant cooling and backup power. Sensitive engineering and production data also stays on dedicated hardware in Israel instead of sitting in a shared public cloud.&lt;/p&gt;

&lt;p&gt;The idea is that each acquired business can tap shared resources while keeping its own independence and specialized knowledge. The platform has room for more subsidiaries as T3 keeps buying companies, which could mean less duplicated infrastructure spending down the road.&lt;/p&gt;

&lt;p&gt;So far, only Rimon is using it, and management hasn’t put numbers on the savings or efficiency gains. For now, this is groundwork for future benefits rather than a proven cost or margin boost.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt; to receive our articles and reports emailed directly to you. Please visit our &lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt; for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/DFNS/default.aspx</link><pubDate>Wed, 18 Nov 2026 15:16:00 -0500</pubDate></item><item><title>QUIT: Looking Ahead to Resubmission</title><guid>eb26604f-b2dc-441f-bcf0-5a5002c464a5</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=dd01b998-53e1-4448-9b1a-8fe0a6a3c606"&gt;John Vandermosten, CFA&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: QUIT&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11182026_QUIT_Vandermosten.pdf"&gt;READ THE FULL QUIT RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;AchieveRx, The Quit Company (NASDAQ: QUIT) continues to make meaningful changes to the company’s image and management team. It has also presented new data at conferences and updated investors on the timeline for resubmission of the new drug application (NDA). Cash and liquid equivalents sit at just over $200 million, providing substantial flexibility to continue pre-commercialization activities and prepare the resubmission of the cytisinicline NDA.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Financial and Operational Results&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Achieve’s 3Q:26 financial and operational results were detailed in a &lt;a href="https://ir.achieverx.com/news-events/press-releases/detail/277/achieverx-reports-third-quarter-2026-financial-results-and-provides-business-updates"&gt;press release&lt;/a&gt; and &lt;a href="https://ir.achieverx.com/sec-filings/all-sec-filings/content/0001193125-26-455463/achv-20260930.htm"&gt;Form 10-Q&lt;/a&gt; filing. No revenues were reported in 3Q:26. Operating expense was $20.5 million leading to a net loss of $12.1 million or $0.11 per share. The difference between operating expense and net loss is attributable to interest income and a change in warrant-related fair value. For the quarter ending September 30&lt;sup&gt;th&lt;/sup&gt;, 2026 versus the same prior year period:&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;Research &amp; development expense totaled $6.2 million, up 17% from $5.3 million, due to an increase in manufacturing and supply chain costs which were associated with manufacturing development, including purchase of raw cytisinicline inventory, finished drug product, packaging and stability expensed to R&amp;D prior to regulatory approval. In addition, employee expenses increased and were associated with severance and increased headcount. Increases were partially offset by a decrease in clinical trial costs which were associated with the ORCA-OL trial, which was completed in October 2025;&lt;/li&gt;
&lt;li&gt;General &amp; administrative expense was $14.3 million, up 53% from $9.4 million due to an increase in stock-based compensation expense, higher employee expenses which were associated with severance, increased headcount and recruitment activity along with greater legal costs. These increases were partially offset by lower commercial launch preparation costs;&lt;/li&gt;
&lt;li&gt;Net interest income was $1.5 million vs. $0.4 million as interest from higher cash balances offset interest expense;&lt;/li&gt;
&lt;li&gt;Other income of $6.9 million was predominantly related to change in fair value of warrant liability, partially offset by other miscellaneous expense;&lt;/li&gt;
&lt;li&gt;Net loss was $12.1 million vs. $14.4 million or $0.11 and $0.28 per share, respectively.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;As of September 30&lt;sup&gt;th&lt;/sup&gt;, 2026, marketable securities, cash and equivalents totaled $201.5 million. This compares to a $36.4 million balance held at the end of 2025. At the end of the third quarter, Achieve carried convertible debt of $13.0 million on the balance sheet. Cash used in operations during the first nine months of 2026 was $26.1 million versus $31.5 million in the same prior year period. Nine-month cash from financing was $190 million which includes net proceeds from the $168 million financing that was funded by a consortium of healthcare investors and the recent exercise of warrants. There are additional warrants that could raise another $150 million which will expire 20 business days following the announcement of FDA approval of cytisinicline. Following the end of the third quarter, Achieve received aggregate proceeds of $1.2 million from further warrant exercise. In August 2026, Achieve entered into an at-the-market (ATM) offering program with Jefferies to sell up to $150 million in common stock.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Chief Financial Officer Transition and Addition of Other Executives&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;On October 5&lt;sup&gt;th&lt;/sup&gt;, 2026, Benjamin Halladay was &lt;a href="https://ir.achieverx.com/news-events/press-releases/detail/271/achieve-life-sciences-appoints-benjamin-halladay-as-chief-financial-officer"&gt;appointed&lt;/a&gt; as Achieve’s Chief Financial Officer, succeeding Mark Oki, who concurrently stepped down from the role. Ben offers more than 15 years of financial management experience across commercial and launch environments. Before joining Achieve, Ben served as the Chief Financial Officer of Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue. During his tenure, Esperion deleveraged its balance sheet and acquired Corstasis Therapeutics and its product Enbumyst. He led the finance workstream through the company’s sale to ARCHIMED for up to $1.1 billion. Earlier, Ben held positions at Pfizer Inc., where he worked on Lipitor and Chantix in the Primary Care business unit, and at National Oilwell Varco, a Fortune 500 global industrial company. He holds an MBA from Fordham University and a BA from Syracuse University and is a Certified Public Accountant (inactive).&lt;/p&gt;

&lt;p&gt;On October 7&lt;sup&gt;th&lt;/sup&gt;, 2026, Achieve &lt;a href="https://ir.achieverx.com/news-events/press-releases/detail/273/achieve-life-sciences-appoints-kaitlyn-tuson-as-senior-vice-president-marketing-and-communications"&gt;announced&lt;/a&gt; that it had appointed Kaitlyn Tuson as its Senior Vice President, Marketing and Communications. She has worked broadly across the healthcare industry supporting companies as fractional Chief Marketing Officer and will lead Achieve’s marketing, brand strategy, and corporate communications as the company prepares for the potential commercialization of cytisinicline. Kait has helped companies bring products and services to market across healthcare, including six pharmaceutical products, three of them blockbuster therapies. Previous roles include marketing and communications for Weill Cornell Medicine’s clinical services organization and with Saatchi &amp; Saatchi Wellness where she was group director of strategy. Ms. Tuson holds a B.A. in Business, Communications and Digital Audiences from the W. P. Carey School of Business at Arizona State University.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;CHEST 2026 Presentation&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The company presented ORCA-OL data at the &lt;a href="https://www.chestnet.org/learning-and-events/events/chest-annual-meeting"&gt;CHEST 2026 annual meeting&lt;/a&gt; held in Phoenix, Arizona from October 18&lt;sup&gt;th&lt;/sup&gt; to 21&lt;sup&gt;st&lt;/sup&gt;. The presentation highlighted the 39% quit rate for new cytisinicline users in the study. Most of the 479 enrolled adults were smokers with a minority either vaping exclusively or smoking and vaping. The population was considered hard-to-treat, where every participant had already made an attempt to quit and had tried other interventions. Participants were in their mid-fifties on average, ranging up to age 79, and many had a history of chronic conditions. Those who smoked had made an average of five quit attempts before starting the study. Quit rates, defined as four-week continuous abstinence, rose over the course of treatment, from 25.5% at weeks 9 to 12 to 31.2% at weeks 49 to 52. At the end of treatment, 39.4% of participants new to cytisinicline had quit, as had 27.8% of those who had taken cytisinicline in a prior trial and were still smoking or vaping. Cytisinicline was generally well tolerated over the 52 weeks, and the independent Data Safety Monitoring Committee (DSMC) identified no new safety signals.&lt;/p&gt;

&lt;p style="text-align: center;"&gt;&lt;a href="https://d1io3yog0oux5.cloudfront.net/_3d916cad030da919496e75fe797b6bf0/achievelifesciences/db/1085/11788/pdf/QUIT_Corporate_Deck_Final.pdf"&gt;&lt;img src="//s27.q4cdn.com/906368049/files/pictures/2026/11182026_QUIT_1.png" style="width: 650px;" /&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Name and Ticker Change – AchieveRx, The QUIT Company&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Achieve announced a name and ticker change to AchieveRx, The Quit Company (NASDAQ: QUIT) in an early November &lt;a href="https://achieverx.com/achieve-life-sciences-becomes-achieverx-the-quit-company-and-will-trade-under-the-ticker-quit/"&gt;press release&lt;/a&gt;. The change became effective on November 10&lt;sup&gt;th&lt;/sup&gt; and presents the company in the context of its mission to develop medicine for quitting smoking and vaping. Three ideas guide the company: Simplicity, Science and Second Chances, for good. CEO Andrew Goldberg references his own experiences as a physician as a reason for his drive to lead the company in this objective.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt;&amp;nbsp;to&amp;nbsp;receive our articles and reports emailed directly to you. Please visit our&amp;nbsp;&lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt;&amp;nbsp;for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/QUIT-Looking-Ahead-to-Resubmission-article/default.aspx</link><pubDate>Wed, 18 Nov 2026 14:02:00 -0500</pubDate></item><item><title>PRE: Hitting All the Right Notes</title><guid>b8ae34ed-e1d5-4812-9876-f8c825a163aa</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=c9477f93-8bd2-4293-9461-8d809f2a916c"&gt;Brad Sorensen, CFA&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: PRE&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11182026_PRE_Sorensen.pdf"&gt;READ THE FULL PRE RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Prenetics Global Limited (NASDAQ: PRE) delivered another impressive demonstration of the growth potential of its IM8 consumer wellness platform with third-quarter 2026 financial results. The results reinforce the company's transformation into a rapidly expanding global health and nutrition business, while providing increasingly compelling evidence that its growth is supported by strong customer retention, attractive customer economics, and a highly scalable business model. Perhaps most importantly to us and to investors, management is demonstrating that it can acquire customers at increasingly efficient rates while those customers continue generating revenue long after their initial purchases.&lt;/p&gt;

&lt;p&gt;IM8 has emerged as one of the fastest-growing brands in premium nutritional supplements. Its flagship Daily Ultimate Essentials product combines 90 ingredients into a convenient daily drink designed to simplify consumers' health and wellness routines. The brand's combination of premium positioning, science-backed formulations, subscription-based purchasing, and high-profile global partnerships has allowed Prenetics to establish a meaningful presence in an enormous and fragmented market in less than two years.&lt;/p&gt;

&lt;p&gt;The 3Q results provide additional evidence that IM8 is developing into considerably more than a successful new supplement brand. It is increasingly demonstrating the characteristics of a recurring-revenue consumer business with substantial opportunities to expand its customer base, introduce complementary products, and improve profitability as it scales.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Record Third-Quarter Results Demonstrate Exceptional Growth&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Prenetics reported third-quarter revenue of $64.1 million, an increase of approximately 228% from the prior year and 37.9% sequentially. Revenue exceeded management's previous guidance of $63 million to $64 million, providing another example of the company delivering on its stated growth objectives.&lt;/p&gt;

&lt;p&gt;IM8 accounted for $62.9 million of quarterly revenue, representing approximately 266% year-over-year growth and nearly 40% sequential growth. This marked the brand's seventh consecutive record quarter, an impressive achievement for a business that launched in December 2024.&lt;/p&gt;

&lt;p&gt;The company's performance accelerated throughout the quarter, with September generating $23.7 million in IM8 revenue, its strongest month ever. Annualizing September's revenue produces a run rate of approximately $284 million, highlighting how rapidly the business has expanded from virtually no revenue less than two years earlier. Although this run rate is not the same as contracted recurring revenue or a full-year forecast, it provides an indication of the sales momentum entering the final quarter of 2026.&lt;/p&gt;

&lt;p&gt;Importantly, management reaffirmed its full-year 2026 total revenue guidance of $220 million to $230 million, including $215 million to $222 million from IM8. The company also maintained its expectation for IM8 to generate more than $400 million in revenue during 2027. This outlook is particularly encouraging because it is based entirely on existing products, without contributions from several significant expansion initiatives scheduled for next year.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Customer Retention and Economics Strengthen the Investment Case&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In our view, the most important information in today's shareholder letter and investor presentation concerns the economics of customer acquisition and retention. Rapid revenue growth can be expensive and difficult to sustain, especially in a consumer business that depends heavily on marketing. Prenetics, however, is providing increasingly substantial evidence that its customer acquisition investments are producing attractive long-term returns.&lt;/p&gt;

&lt;p&gt;The approximately 27,000 customers acquired during IM8's first full quarter of operations in early 2025 have already generated gross profit equal to approximately 4.1 times their original acquisition cost in less than two years. This exceeds the commonly referenced three-to-one lifetime-value-to-acquisition-cost benchmark for subscription businesses, and those customers continue to purchase products.&lt;/p&gt;

&lt;p&gt;Even more encouraging, another 91,000 customers acquired subsequently are on pace to exceed that benchmark in early 2027, according to management's projections. Prenetics also reported that a January 2026 customer cohort recovered its acquisition costs through gross profit in approximately six months, indicating that newer customers can potentially become economically attractive relatively quickly.&lt;/p&gt;

&lt;p&gt;The company is also becoming more efficient at attracting those customers. Average customer acquisition cost declined to approximately $285 in the third quarter, compared with roughly $301 in the second quarter and $305 in the first. This improvement occurred even as acquisition spending increased, suggesting that the IM8 brand is becoming more effective at converting marketing investment into new customers.&lt;/p&gt;

&lt;p&gt;Retention figures provide further support for our belief in the durability of IM8's revenue model. Approximately 59% of third-quarter direct customer billings came from repeat purchases, totaling $37.5 million. Prenetics ended September with approximately 160,000 active subscriptions.&lt;/p&gt;

&lt;p&gt;The independent customer data presented by Prenetics is particularly interesting to us. According to U.S. credit and debit card data from Indagari, IM8 demonstrated stronger customer purchasing persistence than AG1, Grüns, and Thorne in the measured cohort. Approximately 11% of IM8 customers were still purchasing in their 22nd month, compared with 7.4% to 8.7% for the three competing brands. The same dataset showed significantly greater growth in observed IM8 sales than its competitors during the first nine months of 2026. These figures are based on a third-party sample rather than the entire market, but they provide encouraging outside validation of the company's internal customer metrics.&lt;/p&gt;

&lt;p&gt;For investors, we believe the implications are substantial. A business that retains customers for extended periods, earns attractive margins on repeat purchases, and recovers acquisition costs relatively quickly can reinvest aggressively in growth while developing an increasingly valuable existing customer base.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Improving Operating Leverage and a Clearer Path to Profitability&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Another important development in Prenetics' third-quarter results is the emergence of meaningful operating leverage. While the company remains unprofitable, several underlying financial measures are improving as revenue grows.&lt;/p&gt;

&lt;p&gt;Prenetics generated approximately $40.7 million in gross profit during the quarter, representing a gross margin of roughly 64%. This compares with 65% in the previous quarter, with the modest decline largely attributable to inventory provisions and write-offs associated with an earlier product formulation. Management expects additional manufacturing capacity, including a new manufacturer scheduled to come online in early 2027, to support future production efficiencies and potentially improve margins.&lt;/p&gt;

&lt;p&gt;Perhaps more significant is the improvement in operating expenses relative to revenue. Operating costs, as defined in management's financial framework, declined from approximately 25% of revenue in the first quarter to 16% in the third quarter. Selling and marketing expenses also improved as a percentage of sales, falling from 89% in the second quarter to 74% in the third quarter despite an increase in absolute marketing expenditures.&lt;/p&gt;

&lt;p&gt;The resulting improvement in adjusted EBITDA is particularly encouraging to us. Prenetics reported a third-quarter adjusted EBITDA loss of $12.7 million, equivalent to approximately 20% of revenue, compared with a loss equivalent to 39% of revenue in the second quarter. The company also generated $30.6 million in contribution profit, representing a 48% contribution margin before customer acquisition marketing and brand-partner costs.&lt;/p&gt;

&lt;p&gt;These figures demonstrate that the underlying business is developing a substantial gross profit base, even as management continues investing aggressively in attracting new customers. As the proportion of revenue generated by existing customers increases, Prenetics should have an opportunity to reduce marketing expenses as a percentage of revenue and convert more of its gross profit into operating earnings.&lt;/p&gt;

&lt;p&gt;Management is deliberately prioritizing growth over near-term profitability and we are in full support of this approach and believe it is the appropriate one for long-term value creation for shareholders. Reflecting this strategy, Prenetics increased its expected second-half 2026 adjusted EBITDA loss to $30 million to $35 million, compared with its previous expectation of $8 million to $12 million. This is a meaningful increase and should not be overlooked. However, management believes that continuing to acquire customers while acquisition economics remain attractive will ultimately create substantially greater long-term shareholder value than reducing marketing spending to accelerate short-term profitability.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Strong Liquidity and Innovative Financing Support Continued Expansion&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Prenetics' financial position is another important element of the investment story. The company ended September with approximately $111.5 million in cash and current financial assets, an increase from $109.4 million at the end of June.&lt;/p&gt;

&lt;p&gt;This liquidity is especially noteworthy given the company's aggressive marketing investments and inventory expansion during the quarter.&lt;/p&gt;

&lt;p&gt;A major reason Prenetics can pursue this strategy is its $1 billion customer acquisition financing arrangement with General Catalyst's Customer Value Fund. Under the agreement, General Catalyst can finance up to 70% of qualifying customer acquisition spending in exchange for a capped share of revenue generated by the associated customer cohorts.&lt;/p&gt;

&lt;p&gt;The financing provided approximately $31.6 million of net funding during the third quarter. After incorporating that funding, Prenetics reported positive adjusted free cash flow of $4.1 million, meeting a commitment made in its previous shareholder letter.&lt;/p&gt;

&lt;p&gt;It is important to distinguish this adjusted measure from conventional free cash flow. Prenetics used $27.5 million in operating cash during the quarter, and the reported positive adjusted free cash flow includes external financing proceeds. Nevertheless, the arrangement provides a potentially valuable mechanism for financing growth without issuing new common shares, although it creates repayment obligations linked to future customer revenue.&lt;/p&gt;

&lt;p&gt;For shareholders, this structure is attractive because Prenetics can finance much of its customer acquisition strategy through a dedicated capital partner while preserving more of its existing resources for product development, inventory, research, and expansion into new markets. Management also completed a $40 million share repurchase program earlier in 2026, demonstrating a willingness to return capital when appropriate.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Multiple Growth Catalysts Could Accelerate the Business in 2027&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Although today's financial results are impressive, we are even more excited about the company's anticipated expansion opportunities that we believe may be equally significant for longer-term investors.&lt;/p&gt;

&lt;p&gt;The first major catalyst is the planned launch of IM8 Hydration in the first quarter of 2027. Hydration represents a natural extension of the IM8 platform into a large category with broad appeal beyond the brand's existing core nutritional supplement customers. By offering an additional daily-use product to its existing subscriber base, Prenetics has an opportunity to increase average revenue per customer without necessarily incurring substantial additional acquisition costs.&lt;/p&gt;

&lt;p&gt;Another potentially important initiative is the recently announced 10-year exclusive partnership with Authentic Brands Group to create Care Bears by IM8. Expected to launch in the first half of 2027, this product line will initially focus on gummy multivitamins for children and adults. The partnership allows Prenetics to leverage a widely recognized consumer brand to establish a presence in family-oriented wellness products.&lt;/p&gt;

&lt;p&gt;Authentic Brands Group will also become a strategic shareholder in Prenetics, aligning the interests of the two companies.&lt;/p&gt;

&lt;p&gt;These launches represent more than opportunities to introduce additional products. They could expand IM8's addressable customer population, increase revenue from existing customers, improve lifetime customer value, and create additional opportunities to develop a broader portfolio of premium wellness brands.&lt;/p&gt;

&lt;p&gt;Prenetics is also planning to expand its distribution channels. IM8 currently operates primarily through direct-to-consumer sales, shipping products to customers in 46 countries. Management intends to enter retail distribution and the Chinese market by the end of 2027, potentially providing access to substantial additional customer populations.&lt;/p&gt;

&lt;p&gt;The company's recent partnership with the NBA in Australia and eight Southeast Asian markets should further enhance IM8's international visibility. Combined with its existing relationships with Beckham and other prominent athletes and entertainers, these arrangements give Prenetics considerable global marketing reach.&lt;/p&gt;

&lt;p&gt;Finally, it’s important to understand that none of these proposed new products, retail initiatives, or Chinese market expansion opportunities are included in management's more than $400 million IM8 revenue guidance for 2027. If executed successfully, they could create meaningful upside to the company's existing revenue projections.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Scientific Validation Could Strengthen IM8's Competitive Position&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;An additional aspect of Prenetics' long-term strategy that we believe sets it apart from many of its competitors is its commitment to supporting its products through clinical research rather than relying exclusively on celebrity endorsements and traditional consumer marketing.&lt;/p&gt;

&lt;p&gt;The company currently has three additional randomized, placebo-controlled studies underway. These include a study involving 100 healthcare workers at Mayo Clinic in Florida, a 180-participant longevity study, and a 135-participant gut-health study. The latter two studies are expected to report results by the end of the first quarter of 2027.&lt;/p&gt;

&lt;p&gt;These programs could become important competitive differentiators if they produce convincing evidence supporting the benefits of IM8's formulations.&lt;/p&gt;

&lt;p&gt;With a global supplement market estimated by management at approximately $200 billion annually, consumer trust and product differentiation are important considerations. The ability to combine recognizable branding, convenient daily formulations, and credible clinical evidence could help Prenetics distinguish its products in a crowded marketplace.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Investment Outlook: Building a Potential Global Consumer Health Franchise&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Prenetics' November 18 announcement, shareholder letter, and investor presentation collectively strengthen the investment case for PRE in our opinion. The company continues to deliver exceptional revenue growth while providing increasingly persuasive evidence that its customers remain engaged, purchase repeatedly, and generate attractive returns on acquisition spending.&lt;/p&gt;

&lt;p&gt;Perhaps the most important development is that IM8's business model is becoming more measurable. Prenetics is no longer asking investors to rely solely on projections for a newly launched consumer product. It can now point to actual customer cohorts with nearly two years of purchasing history, declining quarterly acquisition costs, growing repeat revenue, and evidence of improving operating leverage.&lt;/p&gt;

&lt;p&gt;The combination of these characteristics creates a potentially powerful financial model. Each new customer represents not simply an initial product sale, but an opportunity to generate recurring revenue and introduce additional products over time. As the customer base expands, the company has the potential to improve profitability through increased purchasing activity, manufacturing efficiencies, and greater leverage of its existing infrastructure.&lt;/p&gt;

&lt;p&gt;Nevertheless, the company's financial performance and expanding strategic opportunities suggest that Prenetics is moving beyond the earliest stages of brand development and into a period where the scale of its business could increase substantially.&lt;/p&gt;

&lt;p&gt;Management's reaffirmation of more than $400 million in IM8 revenue for 2027, excluding several potentially meaningful new growth initiatives, provides an especially encouraging foundation for future expectations. Strong international brand recognition, growing recurring customer revenue, substantial liquidity, and dedicated acquisition financing further enhance its competitive position.&lt;/p&gt;

&lt;p&gt;For investors willing to accept the risks associated with an aggressively expanding, currently unprofitable consumer business, PRE presents an increasingly compelling growth opportunity that we believe will reward shareholders. Its latest results suggest that IM8 is developing the customer loyalty, financial characteristics, and global reach necessary to become a significant participant in the premium health and wellness market. Continued execution could translate that operating momentum into substantial long-term shareholder value.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt; to receive our articles and reports emailed directly to you. Please visit our &lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt; for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/PRE-Hitting-All-the-Right-Notes/default.aspx</link><pubDate>Wed, 18 Nov 2026 12:49:00 -0500</pubDate></item><item><title>COCP: Phase 1b Norovirus Challenge Study Results Near Year-End 2026</title><guid>d45d3fd2-bb88-4a5c-8b66-bcf8612cdc73</guid><description>&lt;span&gt;
  &lt;p&gt;By &lt;a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=e38a3af7-5620-44ff-b299-706e26bed702"&gt;David Bautz, PhD&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;stock_ticker&gt;NASDAQ: COCP&lt;/stock_ticker&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href="https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_11182026_COCP_Bautz.pdf"&gt;READ THE FULL COCP RESEARCH REPORT&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Business Update&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Last Patient Dosed in Phase 1b CDI-988 Norovirus Study; Topline Results at Year-End 2026&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Cocrystal Pharma, Inc. (NASDAQ: COCP) is continuing its Phase 1b human challenge study of CDI-988 to evaluate its potential to prevent and treat norovirus infection. In September 2026, the company announced that the last subject had been dosed and that no serious adverse events had been reported to date. We anticipate preliminary efficacy results at year-end 2026. CDI-988 is an oral, direct-acting antiviral designed to inhibit the highly conserved 3CL protease required for norovirus replication. The drug received Fast Track designation from the FDA in April 2026, which could facilitate more frequent interactions with the agency, a rolling review of an eventual NDA, and makes the drug eligible for Priority Review.&lt;/p&gt;

&lt;p&gt;The Phase 1b human challenge study initiated at Emory University in March 2026. The study uses a controlled norovirus challenge model in healthy adults, initially evaluating the infectivity of the GII.2 Snow Mountain Virus inoculum before advancing into prevention and treatment cohorts in which subjects receive CDI-988 or placebo. The first cohort was completed in 1Q26, after which the company began enrollment into the active prevention and treatment cohorts.&lt;/p&gt;

&lt;p&gt;The study design is particularly useful for an early proof-of-concept trial because the controlled challenge model allows the company to evaluate CDI-988 against a defined viral exposure rather than waiting for naturally occurring infections. The study is intended to assess both clinical and virologic effects, providing an initial indication of whether CDI-988 can prevent infection or reduce the severity and duration of disease once infection has occurred.&lt;/p&gt;

&lt;p&gt;The Phase 1 data provide a reasonable foundation heading into the challenge study. Previously reported results showed CDI-988 was well tolerated across single- and multiple-ascending dose cohorts up to 1,200 mg, with no severe treatment-emergent adverse events, clinically relevant ECG changes or clinically significant pathology findings. The 1,200 mg dose was subsequently selected for the Phase 1b study, in which CDI-988 is administered twice daily for five days.&lt;/p&gt;

&lt;p&gt;Positive results from the Phase 1b study, which could include a meaningful reduction in infection, viral shedding, and/or clinical disease in the controlled challenge setting, would provide the first clinical evidence supporting CDI-988’s mechanism and support discussions regarding subsequent development, partnerships, and financing.&lt;/p&gt;

&lt;p&gt;There are no approved therapies for norovirus infection, which is the most common cause of acute gastroenteritis. According to the Centers for Disease Control (CDC), there are an estimated 685 million cases and 200,000 deaths caused by norovirus infection each year worldwide. In the U.S., norovirus infection causes over 2 million outpatient clinical visits annually and approximately 100,000 hospitalizations. Norovirus prevention and/or therapy is particularly relevant for the military, where a pathogen of that nature can result in significant operational risks. There are multiple military installations, for instance on navy vessels, where norovirus could spread rapidly and possibly hinder combat readiness. Due to this, work on CDI-988 may qualify for various military-sponsored grants or other funding mechanisms, however we are unaware of any specifics at this point.&lt;/p&gt;

&lt;p&gt;CDI-988 was developed using Cocrystal’s proprietary drug discovery platform technology. It binds to a highly conserved region in the active site of noroviruses and coronaviruses 3CL viral proteases and exhibits pan-viral activity against pandemic norovirus and coronavirus strains.&lt;/p&gt;

&lt;p style="text-align: center;"&gt;&lt;img src="//s27.q4cdn.com/906368049/files/pictures/2026/11182026_COCP_1.png" style="width: 650px;" /&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Financial Update&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;On November 15, 2026, Cocrystal announced financial results for the third quarter of 2026. The company received a $500,000 Small Business Innovation Research (SBIR) Phase I award from the NIH to support the development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Grant income is earned as the company incurs costs for the program. Grant income for the third quarter of 2026 was $105,000 compared to $0 for the third quarter of 2025. R&amp;D expenses for the third quarter of 2026 were $2.0 million compared to $1.0 million in the third quarter of 2025. The increase was primarily due to CDI-988 entering into the Phase 1 clinical trial in 2026. G&amp;A expenses in the third quarter of 2026 were $1.6 million compared to $1.1 million in the third quarter of 2025. The increase was primarily due to an increase in salaries and wages, investor and public relation expenses, and legal expenses.&lt;/p&gt;

&lt;p&gt;Cocrystal exited the third quarter of 2026 with approximately $4.9 million in cash and cash equivalents. On August 3, 2026, Cocrystal announced a private placement with OPKO Health in which 5,474,053 shares of common stock were sold for $5.0 million, or $0.9134 per share. Importantly, the financing did not include warrants or other derivative securities. The transaction represents continued financial support from OPKO, which has been a longtime investor in Cocrystal. Philip Frost, the Chairman and CEO of OPKO, is a co-founder, director, and principal stockholder of Cocrystal. As of November 16, 2026, the company had approximately 19.3 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of 27.6 million.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;u&gt;Conclusion&lt;/u&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;We look forward to the preliminary results from the Phase 1b challenge study of CDI-988 for the prevention and treatment of norovirus infection near the end of 2026. These will be the first efficacy results for CDI-988 and will help to guide next steps for the program. With no approved therapies or vaccines, norovirus remains a significant global health threat that offers a substantial market opportunity. With no changes to our model, our valuation remains at $8 per share.&lt;/p&gt;

&lt;p&gt;&lt;strong style=""&gt;&lt;a href="https://scr.zacks.com/subscribe/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;SUBSCRIBE TO ZACKS SMALL CAP RESEARCH&lt;/b&gt;&lt;/a&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="font-size: 12px;"&gt;&lt;b style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i&gt; to receive our articles and reports emailed directly to you. Please visit our &lt;/i&gt;&lt;/b&gt;&lt;a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;"&gt;&lt;b&gt;&lt;i&gt;website&lt;/i&gt;&lt;/b&gt;&lt;/a&gt;&lt;/span&gt;&lt;b style="color: rgb(0, 0, 0); text-size- adjust: auto;"&gt;&lt;i&gt;&lt;span style="font-size: 12px;"&gt; for additional information on Zacks SCR.&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;strong style=""&gt; &lt;/strong&gt;&lt;p&gt;&lt;strong style=""&gt;&lt;/strong&gt;&lt;strong style=""&gt;&lt;span style="font-size: 14px;"&gt;&lt;span style="color: rgb(0, 0, 0); text-size-adjust: auto;"&gt;&lt;i style="font-size: 10px;"&gt;DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer &lt;a href="https://scr.zacks.com/disclaimer/default.aspx" style="color: rgb(242, 132, 16);"&gt;HERE&lt;/a&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/span&gt;</description><link>https://scr.zacks.com/news/news-details/2026/COCP-Phase-1b-Norovirus-Challenge-Study-Results-Near-Year-End-2026-article/default.aspx</link><pubDate>Wed, 18 Nov 2026 12:13:00 -0500</pubDate></item></channel></rss>